使精准治疗成为现实。

免疫肿瘤学与免疫治疗

联系我们

Access over 30 different syngeneic tumor models, from both solid and disseminated origins as well as access to commercially generated humanized mouse models or client-generated models.

借鉴过去10年的超过1000项免疫肿瘤学临床研究经验。

Partner with an oncology CRO provider who has served nearly 20,000 immuno-oncology patients in clinical trials in the last 5 years.

Immuno-oncology (I/O) has become a significant opportunity for oncology drug discovery and development. 充分利用每个人特有的免疫系统来减轻肿瘤细胞致命作用的能力导致了精准医药的爆炸式增长。 Integrate your flow cytometry, efficacy models, imaging, biomarker, and companion diagnostics to quickly advance to the next milestone--because patients can't wait.

临床前免疫治疗

以富有意义的方式评估特定肿瘤模型研发所涉及的免疫效应细胞和介导个别疗法抗肿瘤反应的免疫效应细胞十分重要。对于我们的许多模型而言,我们都有增长曲线,并且我们将继续建立针对相应药物(例如抗CTLA-4、抗PDL-1和抗PD-1抗体)的数据库。

In addition to testing immune-modulating agents themselves or testing other agents in combination with immune-modulators, it is important to consider the impact of radiation therapy, which is being integrated into and increasingly investigated in combination with these immuno-oncology protocols. 表明放疗和免疫调节剂的远端效应以及直接联合的抗肿瘤作用的数据已提供了概念验证,并且正在临床前环境中对该高度利用的临床相关模式进行进一步的研究。

临床免疫肿瘤学

要使精准医疗取得成效,必须采用创新方法进行快速试验,并向合适的个人提供合适的疗法。 At Labcorp, we have proven experience in immuno-oncology studies, including over 100 protocols in the past five years, performed in 58 countries at more than 2,860 sites with over 19,750 patients.

我们对超过70%通过FDA批准的伴随诊断产品的支持也体现出我们对肿瘤免疫研发的承诺。作为近期关键性III期注册试验的一部分,我们的中心实验室是PD-L1表达试验的唯一供应商,这促成了FDA对一项新的OPDIVO®(nivolumab)诊断测试的审批。此外,我们同类最佳的伴随诊断能力支持TagrissoTM(osimertinib)及其EGFR突变试验以及免疫疗法Keytruda®(pembrolizumab)及其PD-L1伴随诊断通过了审批。

让我们开始对话

联系我们